Rupatadine is a additional bearing antihistamine and PAF adversary acclimated to amusement allergies. It was apparent and developed by J. Uriach y Cia, S. A. and is marketed beneath several barter names such as Rupafin, Alergoliber, Rinialer, Pafinur, Rupax and Ralif.
Rupatadine discovery, pre-clinical and analytic development was performed by J. Uriach y Cia, S. A., a Spanish biologic company. It was launched in 2003 in Spain by J. Uriach y Cia, S. A., with the cast name of Rupafin. The allotment of the artefact is accustomed in 23 countries from the EU, 8 Central American countries, Brazil, Argentina, Chile, Turkey and 14 African countries.